Page last updated: 2024-10-29

isradipine and Cardiomyopathy, Hypertrophic Obstructive

isradipine has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 2 studies

Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

Research Excerpts

ExcerptRelevanceReference
"Treatment with the new calcium antagonist isradipine significantly reduced diastolic blood pressure to less than 90 mm Hg in 64% of fourteen blacks with mild or moderately severe essential hypertension."5.06The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients. ( Carr, AA; Prisant, LM, 1990)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carr, AA1
Prisant, LM1
Ferry, DR1
Kaumann, AJ1

Trials

1 trial available for isradipine and Cardiomyopathy, Hypertrophic Obstructive

ArticleYear
The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients.
    American journal of hypertension, 1990, Volume: 3, Issue:1

    Topics: Antihypertensive Agents; Black People; Blood Pressure; Calcium Channel Blockers; Cardiomyopathy, Hyp

1990

Other Studies

1 other study available for isradipine and Cardiomyopathy, Hypertrophic Obstructive

ArticleYear
Relationship between beta-adrenoceptors and calcium channels in human ventricular myocardium.
    British journal of pharmacology, 1987, Volume: 90, Issue:3

    Topics: Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Female; Humans; In Vitro Techniques; Iodoben

1987